EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 32, 2014, Pages 11721-11726

  De, Sarmishtha ^a   Dermawan, Josephine Kam Tai ^a   Stark, George R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SOS PROTEIN;

ARTICLE; BREAST EPITHELIUM; CANCER CELL; CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASMS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SOS1 PROTEIN; UP-REGULATION;

EID: 84905962129     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412390111     Document Type: Article

References (51)

1. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107(3):241-246
2. Perkins ND (2012) The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 12(2):121-132
3. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3): 344-362
4. Perkins ND, Gilmore TD (2006) Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ 13(5):759-772
5. Baltimore D (2011) NF-κB is 25. Nat Immunol 12(8):683-685
6. Lu T, Sathe SS, Swiatkowski SM, Hampole CV, Stark GR (2004) Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene 23(12):2138-2145
7. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB (2007) Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 26(52):7324-7332
8. Yu HG, et al. (2003) Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 65(1):37-45
9. Tang X, et al. (2006) Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107(11):2637-2646
10. Ladanyi M, Pao W (2008) Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond. Mod Pathol 21(Suppl 2):S16-S22
11. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284(1):99-110
12. Wykosky J, Fenton T, Furnari F, Cavenee WK (2011) Therapeutic targeting of epidermal growth factor receptor in human cancer: Successes and limitations. Chin J Cancer 30(1):5-12
13. Yang W, et al. (2011) Nuclear PKM2 regulates α-catenin transactivation upon EGFR activation. Nature 480(7375):118-122
14. Hammerman PS, Jänne PA, Johnson BE (2009) Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 15(24):7502-7509
15. Brown M, Cohen J, Arun P, Chen Z, Van Waes C (2008) NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 12(9):1109-1122
16. Yang W, et al. (2012) EGFR-induced and PKCe monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell 48(5): 771-784
17. Habib AA, et al. (2001) The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276(12):8865-8874
18. Chen D, et al. (2003) NIK is a component of the EGF/heregulin receptor signaling complexes. Oncogene 22(28):4348-4355
19. Kapoor GS, Zhan Y, Johnson GR, O'Rourke DM (2004) Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol 24(2):823-836
20. Tanaka K, et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 1(6):524-538
21. Jiang T, et al. (2011) CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer Res 71(6):2183-2192
22. Guo C, Stark GR (2011) FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. Proc Natl Acad Sci USA 108(19):7968-7973
23. Pierre S, Bats AS, Coumoul X (2011) Understanding SOS (Son of Sevenless). Biochem Pharmacol 82(9):1049-1056
24. Buday L, Downward J (2008) Many faces of Ras activation. Biochim Biophys Acta 1786(2):178-187
25. Jorge R, et al. (2002) HSos1 contains a new amino-terminal regulatory motif with specific binding affinity for its pleckstrin homology domain. J Biol Chem 277(46): 44171-44179
26. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D (2007) Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 9(6):706-712
27. Tracy S, et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64(20):7241-7244
28. Bianco C, et al. (2000) Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6(11):4343-4350
29. Ogino H, et al. (2011) E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 10(7):1218-1228
30. Ohashi K, et al. (2013) Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 19(9):2584-2591
31. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73
32. Lu T, et al. (2009) Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci USA 106(38): 16339-16344
33. Okabe T, et al. (2007) Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67(5):2046-2053
34. De S, Cipriano R, Jackson MW, Stark GR (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 69(20):8035-8042
35. Jeng HH, Taylor LJ, Bar-Sagi D (2012) Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Commun 3:1168
36. Jun JE, Yang M, Chen H, Chakraborty AK, Roose JP (2013) Activation of extracellular signal-regulated kinase but not of p38 mitogen-activated protein kinase pathways in lymphocytes requires allosteric activation of SOS. Mol Cell Biol 33(12):2470-2484.
37. Häussler U, von Wichert G, Schmid RM, Keller F, Schneider G (2005) Epidermal growth factor activates nuclear factor-kappaB in human proximal tubule cells. Am J Physiol Renal Physiol 289(4):F808-F815
38. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B (2010) EGFR-mutated lung cancer: A paradigm of molecular oncology. Oncotarget 1(7):497-514
39. Alberti C, et al. (2012) Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 31(37):4139-4149
40. Ma C, et al. (2013) Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells. Oncol Rep 29(2):812-818
41. Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805(2): 167-180
42. Bivona TG, et al. (2011) FAS and NF-7kappa;B signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523-526
43. Gurova KV, et al. (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102(48):17448-17453
44. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010) Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285(25):19162-19172
45. Douville E, Downward J (1997) EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene 15(4):373-383
46. Buday L, Warne PH, Downward J (1995) Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 11(7):1327-1331
47. Orton RJ, Sturm OE, Gormand A, Wolch W, Gilbert DR (2008) Computational modelling reveals feedback redundancy within the epidermal growth factor receptor/extracellular-signal regulated kinase signalling pathway. IET Syst Biol 2(4):173-183
48. Watanabe T, et al. (2000) Significance of the Grb2 and son of sevenless (Sos) proteins in human bladder cancer cell lines. IUBMB Life 49(4):317-320
49. Timofeeva OA, et al. (2009) Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol 35(4):751-760
50. Guerrero C, et al. (1996) Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines. Oncogene 12(5):1097-1107
51. Sibilia M, et al. (2000) The EGF receptor provides an essential survival signal for SOSdependent skin tumor development. Cell 102(2):211-220.